- Home
- ENSC vs SNGX Comparison
ENSC vs SNGX Comparison
Compare ENSC & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- SNGX
- Stock Information
- Founded
- ENSC 2003
- SNGX 1987
- Country
- ENSC United States
- SNGX United States
- Employees
- ENSC N/A
- SNGX N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- SNGX Health Care
- Exchange
- ENSC Nasdaq
- SNGX Nasdaq
- Market Cap
- ENSC 5.5M
- SNGX 6.1M
- IPO Year
- ENSC N/A
- SNGX 1987
- Fundamental
- Price
- ENSC $2.29
- SNGX $2.08
- Analyst Decision
- ENSC
- SNGX
- Analyst Count
- ENSC 0
- SNGX 0
- Target Price
- ENSC N/A
- SNGX N/A
- AVG Volume (30 Days)
- ENSC 31.4K
- SNGX 29.1K
- Earning Date
- ENSC 05-12-2025
- SNGX 05-09-2025
- Dividend Yield
- ENSC N/A
- SNGX N/A
- EPS Growth
- ENSC N/A
- SNGX N/A
- EPS
- ENSC N/A
- SNGX N/A
- Revenue
- ENSC $5,210,031.00
- SNGX $119,371.00
- Revenue This Year
- ENSC N/A
- SNGX N/A
- Revenue Next Year
- ENSC N/A
- SNGX N/A
- P/E Ratio
- ENSC N/A
- SNGX N/A
- Revenue Growth
- ENSC 133.58
- SNGX N/A
- 52 Week Low
- ENSC $2.12
- SNGX $1.83
- 52 Week High
- ENSC $14.67
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- ENSC 20.64
- SNGX 35.08
- Support Level
- ENSC $2.19
- SNGX $2.25
- Resistance Level
- ENSC $2.70
- SNGX $2.28
- Average True Range (ATR)
- ENSC 0.32
- SNGX 0.12
- MACD
- ENSC -0.06
- SNGX -0.02
- Stochastic Oscillator
- ENSC 5.69
- SNGX 8.42
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).